Artwork

Content provided by Jayanth Sridhar. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jayanth Sridhar or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 147: CEP290 mRNA intravitreal therapy for LCA

45:25
 
Share
 

Manage episode 224391075 series 1424443
Content provided by Jayanth Sridhar. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jayanth Sridhar or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This episodes focuses on a recent publication (https://www.nature.com/articles/s41591-018-0295-0) in Nature Medicine concerning the successful use of an intravitreal oligonucleotide for a form of Leber Congential Amaurosis (LCA). First, Dr. Allen Ho, one of the authors of the paper, rejoins the program to discuss the project and its implications. Then Dr. Matthew Weed returns to offer his perspective as a ophthalmic genetics specialist on this trial compared to other modalities such as Luxturna and what it means for the future. Dr Weed and Dr. Sridhar have no relevant financial disclosures. Dr. Ho has receieved grant funding from Pro QR.
  continue reading

300 episodes

Artwork
iconShare
 
Manage episode 224391075 series 1424443
Content provided by Jayanth Sridhar. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jayanth Sridhar or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This episodes focuses on a recent publication (https://www.nature.com/articles/s41591-018-0295-0) in Nature Medicine concerning the successful use of an intravitreal oligonucleotide for a form of Leber Congential Amaurosis (LCA). First, Dr. Allen Ho, one of the authors of the paper, rejoins the program to discuss the project and its implications. Then Dr. Matthew Weed returns to offer his perspective as a ophthalmic genetics specialist on this trial compared to other modalities such as Luxturna and what it means for the future. Dr Weed and Dr. Sridhar have no relevant financial disclosures. Dr. Ho has receieved grant funding from Pro QR.
  continue reading

300 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide